Hydroxychloroquine safety outcome within approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia
Date
2020Author
Mohana, Abdulrhman
Sulaiman, Tarek
Mahmoud, Nagla
Hassanein, Mustafa
Alfaifi, Amel
Alenazi, Eissa
Radwan, Nashwa
AlKhalifah, Nasser
Elkady, Ehab
Almohaizeie, Abdullah
AboGazalah, Fouad
AlabdulKareem, Khaled
AlGhofaili, Fahad
Jokdar, Hani
Alrabiah, Fahad
Metadata
Show full item recordAbstract
Background: Global healthcare is challenged following the COVID-19 pandemic, since late
2019. Multiple approaches have been performed to relieve the pressure and support existing
healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the
National Healthcare System. Since the 5th of June 2020, 238 outpatient fever clinics were
established nationwide. This study aimed to assess the safety outcome and reported adverse
events from hydroxychloroquine use among suspected COVID-19 patients.
Method: A cross-sectional study included 2,733 patients subjected to MOH treatment
protocol (hydroxychloroquine) and followed-up within 3-7 days after initiation. Data was
collected through an electronic link and cross-checked with the national database (Health
Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality
(M&M) Committee.
Results: 240 patients (8.8%) discontinued treatment because of side effects (4.1%) and for
non-clinical reasons in the remaining (4.7%). Adverse effects were reported among (6.7%) of
all studied participants, including mainly cardiovascular (2.5%, 0.15% with QTc prolongation),
and gastrointestinal (2.4%). No Intensive Care Unit admission or death were reported among
these patients.
Conclusion: Our results show that hydroxychloroquine for COVID-19 patients in mild to
moderate cases in an outpatient setting, within the protocol recommendation and
inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.
Link to resource
https://doi.org/10.1016/j.ijid.2020.10.031Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.